Off-market insider buying at BriaCell Therapeutics (BCT)

Off-market insider buying at BriaCell Therapeutics (T:BCT)

William Williams, CEO and Director, acquired 6,528,572 Common Shares on a direct ownership basis at a price of $0.070 through a private transaction on September 9th, 2019. This represents a $457,000 investment into the company's shares and an account share holdings change of 57.0%.

Vaughn Embro-Pantalony, a Director, acquired 1,428,571 Common Shares on a direct ownership basis at a price of $0.070 through a private transaction on September 9th, 2019. This represents a $100,000 investment into the company's shares and an account share holdings change of greater than 100%.

BriaCell Therapeutics is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

BriaCell Therapeutics Corp. is a Canada-based immuno-oncology biotechnology company, which develops treatments for cancer. Its lead product candidate, Bria-IMT, is being tested in a clinical trial in combination with pembrolizumab in patients with advanced breast cancer. The Company also is developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer patients, and BriaDX, its companion diagnostic test. The Company's preclinical small molecule program consists of protein kinase C delta inhibitors for cancer and fibrotic diseases.